Skip to main content

Table 1 Clinical characteristics of the 22 study participants who remained negative for autoantibodies: GADA, IA-2A, and ICA 1, 6, and 12 months after diagnosis of type 1 diabetes

From: Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies

Patient

Age

Sex

BMI (kg/m2)

HbA1C 0 (%)

IDAA1C 1

IDAA1C 6

IDAA1C 12

Ins dose1 (U/kg/day)

ins dose6 (U/kg/day)

Ins dose12 (U/kg/day)

Cpep1 (pmol/L)

Cpep6 (pmol/L)

Cpep12 (pmol/L)

BGstim1 (mmol/L)

BGstim6 (mmol/L)

BGstim12 (mmol/L)

1

16.3

female

31.14

11.8

Na

7.1

6.8

0.33

0.22

0.33

1055

201

272

14.33

10

9.1

3

6.6

female

14.31

6.3

Na

Na

7.3

Na

Na

0.22

416

79

208

8.7

7.5

10.6

4

14.2

female

14.9

12.8

11.5

8.5

10

0.24

0.22

0.51

902

617

735

8.9

11.4

15.9

6

6.7

male

12.8

9.1

10.2

8.1

8.7

0.33

0.3

0.46

392

413

277

13.7

14.5

11.4

7

1.4

male

13.7

11.1

10.3

8.2

10.6

0.25

0.23

0.5

184

67

21

13.2

13.4

15.6

9

7

male

14.26

9

9.2

9.4

11.7

0.33

0.38

0.74

18

21

13

8.9

10.2

8.4

10

10.8

female

17.6

10.4

10.6

8.4

8.6

0.63

0.49

0.56

592

472

320

11.1

19.9

20.7

11

14.2

female

15.1

14.2

15.6

10.9

10.8

1.10

0.77

0.71

411

347

291

15.6

18.7

20.7

12

4.7

female

15.7

9.3

11.1

8.2

9.4

0.71

0.52

0.6

238

299

212

7.8

11.7

18.3

14

14.1

male

31.6

12

10.1

6.4

6.5

0.18

0.1

0.1

1353

1517

1147

6.2

5.8

5.0

15

3.6

male

11.5

15.3

13.2

9.8

13.7

0.44

0.39

0.84

479

380

216

10.1

Na

Na

16

11.2

male

16.4

10.9

11.7

7.1

8.0

0.63

0.2

0.41

577

294

590

10.3

7.2

9.2

17

3

female

17.72

8.3

8.6

7.4

7.1

0.39

0.3

0.57

379

252

2721

8.7

5.7

11.4

18

6.3

female

17.2

9.3

9.5

Na

7.8

0.48

0.41

0.38

417

886

495

9.4

12.3

11.7

19

11.3

female

14.4

13.2

12.5

10.8

11.1

0.70

0.94

0.89

514

376

437

14.7

10.7

12.7

20

14

male

19.4

13

12.5

7.4

11.3

0.52

0.37

0.44

374

272

615

10.3

8.9

16.3

21

3.1

male

14.4

11

9.9

9.0

Na

0.25

0.45

0.75

91

101

183

12.5

17.7

19.2

22

3.1

male

14.4

8.6

9.3

9.8

11.0

0.35

0.41

0.64

309

229

176

15.0

18.0

19.9

23

10.5

male

17.3

14.3

Na

11.7

13.0

0.91

1.0

1.4

312

210

156

10.4

14.4

15.7

25

11.1

female

Na

13

11.3

11.7

13.0

0.90

1.0

1.44

292

628

450

7.1

11.1

12.9

26

11.1

female

27.4

10.2

10.9

7.3

7.6

0.52

0.57

0.5

2040

1226

701

6.9

6.3

4.1

27

8.8

female

Na

9

9.4

8.5

10.1

0.30

0.31

0.69

596

482

318

9.4

23.6

20.3

Mean

8.4

 

16.9

11.0

10.9

8.9

9.9

0.49

0.47

0.64

518.4

436.6

489.6

10.4

12.5

14.0

SD

4.2

 

4.9

2.4

1.7

1.6

2.1

0.24

0.27

0.32

448.6

375.8

577.5

2.7

5.1

5.1

  1. Abbreviations: SD, standard deviation; Na, not available; BMI, body mass index; HBA1C0, HBA1C at diagnosis; IDAA1C 1, Insulin Dose Adjusted HbA1c (IDAA1C) at 1 month; IDAA1C 6, IDAA1C at 6 months; IDAA1C 12, IDAA1C at 12 months; Ins dose1, insulin dose at 1 month; Ins dose6, insulin dose at 6 months; Ins dose12, insulin dose at 12 months; Cpep1, stimulated C-peptide at 1 month, Cpep6, stimulated C-peptide at 6 months; Cpep12, stimulated C-peptide at 12 months; BGstim1, 90 min glucose at 1 month; BGstim6, 90 min glucose at 6 months; BGstim12, 90 min glucose at 12 months